Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency

NCT01458067 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01458067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
November 10, 2011
Completion date
February 25, 2016
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer